These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15140279)

  • 21. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.
    Xing Q; Qian X; Li H; Wong S; Wu S; Feng G; Duan S; Xu M; Gao R; Qin W; Gao J; Meng J; He L
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):631-7. PubMed ID: 17105675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone in the treatment of schizophrenia.
    Bravo-Mehmedbasic A
    Med Arh; 2011; 65(6):345-7. PubMed ID: 22299296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.
    Ma L; Zhang X; Xiang Q; Zhou S; Zhao N; Xie Q; Zhao X; Zhou Y; Cui Y
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):94-104. PubMed ID: 30103286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
    Chen SF; Shen YC; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):470-4. PubMed ID: 19302829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
    Peñas-Lledó EM; Dorado P; Cáceres MC; de la Rubia A; Llerena A
    Clin Chem Lab Med; 2007; 45(7):835-8. PubMed ID: 17617023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
    Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
    Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
    Himei A; Okamura T
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.
    Lane HY; Chang YC; Chiu CC; Lee SH; Lin CY; Chang WH
    Psychopharmacology (Berl); 2004 Apr; 172(4):393-9. PubMed ID: 14663551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.
    Charan A; Shewade DG; Rajkumar RP; Chandrasekaran A
    Psychiatry Res; 2016 Jun; 240():209-213. PubMed ID: 27111215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
    Wang L; Fang C; Zhang A; Du J; Yu L; Ma J; Feng G; Xing Q; He L
    J Psychopharmacol; 2008 Nov; 22(8):904-9. PubMed ID: 18308786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia.
    Liu YC; Huang CL; Wu PL; Chang YC; Huang CH; Lane HY
    J Psychopharmacol; 2009 Nov; 23(8):937-43. PubMed ID: 18635704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics.
    Lane HY; Chang YC; Chiu CC; Chen TT; Lee SH; Chang WH
    J Clin Psychopharmacol; 2002 Aug; 22(4):353-8. PubMed ID: 12172333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study.
    Zalsman G; Frisch A; Lev-Ran S; Martin A; Michaelovsky E; Bensason D; Gothelf D; Nahshoni E; Tyano S; Weizman A
    Eur Neuropsychopharmacol; 2003 May; 13(3):183-5. PubMed ID: 12729944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
    Li HQ; Xu JY; Gao YY; Jin L
    Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.